Clinical Trial Update: Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the efficacy and safety of a 12-week triple therapy consisting of danoprevir/ritonavir plus pegylated interferon alfa-2a and ribavirin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Danoprevir/ritonavir (danoprevir/ritonavir)
• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2018-02-07